Title
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
Phase III Trial Comparing Efficacy and Tolerance of Fulvestrant for 3 Years (y) Combined With Anastrozole 5 y Versus Anastrozole 5 y as Adjuvant Hormonotherapy in Postmenopausal With Early Breast Cancer and Positive Hormone Receptors
Phase
Phase 3Lead Sponsor
Spanish Breast Cancer Research GroupStudy Type
InterventionalStatus
Terminated Results PostedIndication/Condition
Breast CancerIntervention/Treatment
fulvestrant anastrozole ...Study Participants
870Postmenopausal women with hormone receptor positive and negative Her2 tumours.
Before randomization, the patients will be stratified according to the center, positive nodes (0 vs. 1-3 vs. ≥4), previous chemotherapy (yes vs no) and hormonal receptors status.
It is expected that disease-free survival for patients receiving Anastrozole alone for 5 years will be up to 90%. An increase of 3% in disease-free survival (DFS) is expected in the arm of Fulvestrant plus Anastrozole, i.e a DFS of up to 93%. They will be required 1358 patients per treatment group (i.e, 2716 patients in total) to give 80% power, alfa bilateral 0.05, and OR 0.6888. Assuming 5% screening failures 2852 patients are required to enter the study. In Jun-2010 the recruitment was stopped due to lack of support of the financier based on the result of Faslodex® and Arimidex® in Combination Trial (FACT-trial), comparing Fulvestrant + Anastrozole vs Anastrozole alone in 1st relapse showed no difference in time to progression at more than 40 months follow-up.
500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
1 mg oral Anastrozole per day during 5 years.
Fulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years
Anastrozole 1 mg will be administered orally as one tablet daily for 5 years.
Inclusion criteria: Histological documentation of breast cancer. Stage I, II, IIIA and IIIC* invasive breast cancer. One of these two characteristics must be fulfilled: N+ T > 1cm *Eligible patients T1-T3 and pN3a (patients with metastasis in infraclavicular nodes would not be eligible) Local treatment with curative intention: mastectomy or tumour excision with free margins + radiotherapy axillary lymphadenectomy or sentinel node biopsy Positive hormone receptors (Estrogen Receptor [ER]+ and/or Progesterone Receptor [PR]+) in primary tumour tissue as measured by a central laboratory Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, defined as immunohistochemistry (IHC) 0 or 1+ or negative fluorescence in situ hybridization (FISH) (in the event of IHC 2+ or 3+) Postmenopausal women, defined as women meeting any of the following criteria: Age ≥ 60 years Age ≥ 45 years with amenorrhea ≥ 12 months in the moment of breast cancer diagnosis and an intact uterus Prior bilateral ovariectomy In case previous hysterectomy, follicle stimulating hormone (FSH) and estradiol levels within the postmenopausal range (using local laboratory ranges)* * In patients previously treated with a luteinizing hormone releasing hormone (LH-RH) analogue, the last extended release formulation should have been administered more than 6 months before randomisation, and menses must not have reappeared. A World Health Organization (WHO) performance status of 0, 1, or 2. Age > 18 years Exclusion criteria: Presence of metastatic disease or bilateral invasive cancer ER and Progesterone Receptor (PR) negative breast cancer HER2-positive breast cancer, defined as FISH+ Treatment with a non-approved or experimental drug within 4 months of randomisation Current malignancy or previous malignancy in the past 5 years (other that breast cancer or basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) Pregnant or nursing patients Any of the following laboratory values within 3 months of randomisation: Platelets < 100 x 109/L Total bilirubin > 1.5 x Upper limit of reference range (ULRR)** ** Patients with documented Gilbert syndrome may be included in this trial Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 2.5 x ULRR A history of: hemorrhagic diathesis (i.e. Disseminated Intravascular Coagulation [DIC], coagulation factor deficiency) or long-term anticoagulant treatment (except for anti-platelet aggregants and low-dose warfarin; see section 3.7) A history of hypersensitivity to the active ingredient or inactive excipients of fulvestrant, aromatase inhibitors, or castor oil Any concomitant severe disease advising against patient participation in the trial o that may jeopardize compliance with the trial protocol, such as uncontrolled heart disease, uncontrolled diabetes mellitus, or uncontrolled severe infections Hormone replacement therapy
| Event Type | Organ System | Event Term | Fulvestrant + Anastrozole | Anastrozole |
|---|
Disease-free survival (DFS) has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years. DFS event is defined as the evidence of local and/or distant recurrence, new primary breast tumour, or death from any cause.
BCsS events has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to BCsS in patients treated with anastrozole for 5 years. BCsS event is defined as the death from breast cancer.
OS event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years. OS event is defined as the death from any cause.
TR event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years. TR event is defined as the evidence of breast cancer recurrence (local and/or distant recurrence of breast cancer, does not include second primary malignancies or deaths from any cause).
